Evidence map›Paper›PMID 35117608›Full record

ArticleTranslational cancer research2020

Incidence, treatment, and survival analysis in mediastinal malignant teratoma population.

Rujuan Wang, Hao Li, Jie Jiang, Guoxing Xu

Open access · diamondAbstract read
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Surgical outcomes in mediastinal mature teratoma.Indian journal of thoracic and cardiovascular surgery · 2025
    Article
  3. Article
  4. Article
  5. [Mediastinal Teratoma: A Pictorial Essay].Taehan Yongsang Uihakhoe chi · 2022
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Rujuan Wang *Department of Respiratory and Critical Care Medicine, The Central Hospital of Wuhan, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China.
Hao Li *Department of Blood Transfusion, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China.
Jie JiangDepartment of Respiratory and Critical Care Medicine, The Central Hospital of Wuhan, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China.
Guoxing XuDepartment of Respiratory and Critical Care Medicine, The Central Hospital of Wuhan, Wuhan Children's Hospital (Wuhan Maternal and Child Healthcare Hospital), Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China.
Central Hospital of Wuhan · CNHuazhong University of Science and Technology · CNWuhan Children's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMediastinal malignant teratoma, as a germ cell tumor, is rare and lacking of population-based study. This study aims to illustrate the incidence, treatment and prognosis of mediastinal malignant teratoma by using a population-based database.

methodsWe gathered clinicopathological data (1975-2016) of malignant teratoma from the Surveillance, Epidemiology and End Results (SEER) database. Then we conducted analysis on the incidence, treatment and prognosis of mediastinal malignant teratoma and other malignant teratomas.

resultsA total of 5,550 cases were in our study cohort, including mediastinal malignant teratoma (n=133) and other malignant teratomas (n=5,417). The incidence of mediastinal malignant teratoma in 2016 was 0.004 per 100,000 persons. Both overall survival (OS) and cancer-specific survival (CSS) of mediastinal malignant teratoma were significantly worse than those of other malignant teratomas (both P<0.001). Surgery significantly improved OS and CSS of either early-staged or all-staged patients with mediastinal malignant teratoma (all P<0.001). However, both chemotherapy and radiotherapy negatively influenced both OS and CSS of patients with mediastinal malignant teratomas (all P<0.001). Besides, compared with surgery alone, combinational therapies like surgery + chemotherapy or surgery + radiotherapy were more harmful to OS and CSS (all P<0.001) of patients with mediastinal malignant teratoma.

conclusionsOur population-based evidence showed that mediastinal malignant teratoma, a rare cancer, had worse prognosis compared with other malignant teratomas. Compared with chemotherapy and radiotherapy, surgery could yield more survival benefits for either early-staged or all-staged patients with mediastinal malignant teratoma. Adjuvant use of chemotherapy/radiotherapy to surgery cannot improve but potentially harm patient prognosis.

Indexed as

malignancyMediastinumsurvival analysisteratomatreatment

Identifiers

PMID35117608
PMCPMC8797871
OpenAlexW3013952029

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.